In the context of cancer staging, we observed that in patients with LIHC classified as stage 1, 2, 3, and 4, the CD320 expression levels in tumor tissues were elevated compared to those in the corresponding non-tumor tissues (Fig. 2A). This evidence concerns the gene CD320 and cancer.